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The active sites of 3 types of aspartic proteases are modeled, based on crystallographic oordinates of endothiapepsin and of a model of HIV-l 
protease. The enthalpies of deprotonation from neutral to mono-anion and to dianion are calculated with semiempirical minimal neglect of differen- 
tial overlap, hydrogen bonding corrected (MNDO/H). This quantum mechanical study of models for the active sites of pepsins, human renin and 
retroviral aspartic proteases demonstrates that the replacements of Thr-218 from pepsins by Ala in human renin and of both Ser-35 and Thr-218 
by alanines in retroviral proteases increases the proton affinity and modulates the charge distribution of those active sites compared to the pepsins. 
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1. I~RODUCTION 
APs are a family of endopeptidases which have many 
common features [l J in addition to structural 
homology [2]. The catalytic machinery includes two 
closely positioned aspartic acids with highly conserved 
neighbor residues. Most APs are maximally active at 
low pH (‘acid proteases’). They have diverse substrate 
specificities but are inhibited, to varying extents, by a 
common inhibitor, pepstatin A [3-51. APs are known 
to be involved in a few disease conditions such as 
AIDS, essential h~rtension, several cancers and 
others f6] and are now a major target for designing in- 
hibitors. 
Recent research establishes that HIV-I protease, 
which processes the gag and pol polyprotein precursors 
towards the production of mature viruses, is an AP [7]. 
Like other retroviral proteases, it has a much shorter 
polypeptide chain than pepsins and renins, and was 
postulated to function in dimeric form [B]. Its crystal 
structure [9,10] confirms those predictions. Other 
divergences of HIV-l protease are the higher pH for 
optimal activity f7,11] compared to pepsins, and its 
much weaker inhibition by pepstatin A [4,7,12] (table 
1). Those characteristics are generally shared by renin 
[13,14]* 
as positions of oxygens from water molecules [18,19]. 
More recently, the structures of renin [ZO], RSV pro- 
tease [21] and HIV-l protease from two sources [9,10] 
have been published. Introduction of inhibitors into the 
crystals further reveals a remarkable rigidity of the ac- 
tive sites of AP except for the ‘flap’ region facing the 
active aspartates [ 19,22,23], This rigidity is primarily 
attributed to intricate hydrogen bonding between the 
active site residues. Fig.1 shows the alignment of 8 ac- 
tive site residues which are crucial for maintaining the 
hydrogen-bonded structure of the catalytic centers. The 
role of the fourth residue of each partial sequence 
(which is mutated in h. renin and retroviral proteases 
compared to pepsins) in regulating the properties of ac- 
tive site aspartates has rarely been addressed and the 
source of optimal pH variations among the AP is poor- 
ly understood [20]. 
A few pepsins have been crystallized and their 
reported high-resolution X-ray structures include coor- 
dinates for the heavy atoms [15-171 (C, N, 0, S) as well 
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The conservation of spatial relations of those 
residues in the crystal structures of many native and in- 
hibited enzymes upports the conclusion that it is possi- 
ble to model the active site of an AP for which only 
primary structure is known, by using the published 
coordinates of another. We have taken this approach to 
study the active sites of h. renin and retroviral proteases 
based on the published coordinates of endothiapepsin. 
Models of renin [24-281 and of HIV-l protease [29] 
were previously constructed for studying their interac- 
tions with inhibitors. However, some details of the 
structure are missing due to the lack of hydrogen coor- 
dinates in X-ray studies of proteins. Some of those pro- 
ton positions are extremely important for hydrogen 
bonding. Correct positioning of the missing protons is 
energy-sensitive and requires a reliable method. 
Semiempirical quantum mechanical studies of H- 
bonding interactions have been recently improved [30] 
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32 33 34 35 215 216 217 216 
PEPSINS: ASP-THR-GLY-SER.-----ASP-THR-GLY- Tb/f? 
H. RENIN: ASP-THR-GLY-SER------ASP-THR-GLY-ALA 
HIV-1 AP: ASP-THR-GLY-ALA------ASP-THR-GLY-ALA 
4 residues). The H-bonding pattern was altered between the two 
aspartic acids both in the neutral and the mono-anionic states to 
study their relative stability. In both of those states, one aspartic acid 
or the other can preferentially contribute the hydrogen bond to 
bridge the oxygens. A subsequent deprotonation leads to the single 
dianionic state. Alternative H-bonding arrangements were tested for 
the aspartates and their neighbors and we report only the most stable 
conformations. In previous calculations [31,32] we discussed the 
small effect of replacing the remote atoms at partial chain terminals 
b) 
T218 
32 
< ,,,, 0, .___........ H _+>_ 
Fig.1. Active site residues of pepsins, human renin and retroviral 
proteases. Residue numbers are from the pepsin system. The two 
partial sequences of retroviral AP are from identical monomers 
which dimerize to form the functional enzyme. Each partial sequence 
of 4 residues is folded so that the terminal Ser and Thr in pepsins can 
form hydrogen bonds with the two aspartates. The mutations of 
those H-bonding residues in human renin and in retroviral proteases 
should affect the properties of the active site [20,34]. Two 
alternatives for H-bonding between the ‘inner’ oxygens (Or, at 
-2.9 A distance) of the aspartates in endothiapepsin are 
schematically drawn for the mono-anionic, presumably ‘active’ state. 
(a) Asp-32 donates an H-bond to anionic Asp-215. Due to the anionic 
nature of this state, Thr-218 donates an H-bond to Asp-215, and 
Ser-35 is a donor to the ‘outer’ oxygen (02) of Asp-32. (b) Asp-215 
is the donor to Asp-32 and the two hydroxylic side chains donate H- 
bonds to the anionic site as in (a). Other H-bonding alternatives (with 
the proton on the ‘outer’ oxygens of the aspartates) are higher in 
energy. In the neutral state, the ‘outer’ oxygen (02) of Asp-215 is 
protonated in (a) and the H-bond from Thr-218 is lost due to 
proton-proton repulsion (see fig.2, upper stereo-pair). The neutral 
equivalent of (b) has another proton on 02 of Asp-32 but Ser-35 
remains a proton donor in the lowest energy alternative, since its 
position is not symmetrical to that of Thr-218. The H-bonding is 
strongly affected by the replacement of Thr-218 by Ala in human 
renin and by replacing both hydroxylic side chains with Ala in 
retroviral AP. 
and allow us to compare alternatives for H-bonding 
[31] and to study the energetics of protona- 
tion/deprotonation and interactions in relatively large 
model systems [32]. 
2. MATERIALS AND METHODS 
Coordinates of 8 residues from the active sites of endothiapepsin 
(4APE) and from the model of HIV-l protease (IHVP), 4 from each 
domain, were extracted from the Brookhaven Data Bank file [33]. 
Hydrogens were added to the structures and their positions were op- 
timized to reach the lowest enthalpy of formation. Only the bond 
lengths, but not angles, were optimized for hydrogen atoms which 
replace backbone carbons at the partial chain terminals (hydrogen 
replacing a carbonyl carbon at the N-H terminals of Asp-32 and 
Asp-215 as well as replacing nitrogens at the C = 0 terminals of each 
1211 
10 
Fig.2. Stereoscopic structures of the neutral active site model of 
endothiapepsin (4APE, upper pair) after the addition of hydrogens 
and energy optimization of their positions. In this structure 
(corresponding to ~01.1, line 1 of table 2), Asp-32 is the H-bond 
donor, and the other proton is on the outer oxygen of Asp-215, 
repulsive towards the possible H-bond from Thr-218. In all the 
structures, the left side residues are from the N-terminal (32-35 in 
pepsin no.). The H-bonds in the rear are from Thr-33 (backbone N- 
H) to Thr-216 (side-chain oxygen) and from Thr-216 (N-H) to Thr-33 
(‘fireman’s grip’). Threonine residues are represented without 
methyls on CD. The middle and lower pairs show, respectively, the 
dianionic states of pepsins and retroviral AP. The acidity of pepsin’s 
active site is greater due to the two hydroxylic H-bonds to the 
aspartates, while in retroviral AP the hydroxylic side chains are 
mutated to alanines and lose this acidity enhancement. 
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Table 1 Table 2 
Inhibition of APs by pepstatin A and their optimal pH for substrate 
cleavage 
Enthalpies of formation in kcal/mol for the neutral, mono-anions 
and dianions in the active site models of pepsins, human renin and 
retroviral AP 
I&o, IO8 (M) pH optimum 
Pepsin 1.4 1.9-3.1 
Cathepsin-D 0.9 3.1-3.3 
Renin 600 6.0-7.0 
AP of HIV-1 110 5.5-5.7 
Values for inhibition of pepsin, cathepsin-D and renin are from I31 
and their pH optima are from [14]. Inhibition of HIV-l AP is from 
[71 and the pH optimum from [7,11 I 
on the acidity of the active site of pepsin. A reduction of the atomic 
presentation by transforming the two terminal NH2 and two terminal 
CH =0 by hydrogens does not have a qualitative effect on the 
relative acidities of the active site. The active site of human renin was 
obtained by replacing the O-H of Thr-218 by hydrogen and re- 
optimizing. Retroviral AP coordinates (‘general retroviral AP’) were 
obtained by a similar replacement of both hydroxyls of Thr-218 and 
Ser-35 from the coordinates of endothiapepsin. HIV-l AP coor- 
dinates are from the model. The structures of pepsin’s neutral active 
site and of the dianionic state for pepsin and retroviral AP are shown 
in fig.2 All calculations were conducted with MNDO/H [30], a 
hydrogen bonding correction to MNDO 1351. 
Pepsin H. renin Retroviral AP 
General HIV-l 
1. Neutral, 32 H-bond - 524.4 -483.9 - 442.2 -371.6 
2. Neutral, 215 H-bond -525.0 - 482.6 -443.9 - 370.2 
3. Mono-anion, 32- - 577.9 - 534.7 - 488.2 - 424.1 
4. Mono-anion, 2IY - 578.6 -531.2 -488.1 -423.5 
5. Dianion - 554.6 - 505.6 -457.1 -407.9 
6. AH, (AAHl) 312.1 (0.0)314.9 (2.8)321.4 (9.3)313.1 (1.0) 
7. AHz (AAH2) 389.8 (0.0)394.8 (5.0)396.9 (7.1)392.0 (2.2) 
The results for HIV-l AP in column 4 are for the model based on 
RSV AP [29]. Two alternatives exist for the neutral structures (lines 
1 and 2 for each model) and for mono-anions (lines 3 and 4). AH1 
is the proton affinity of the more stable mono-anions (difference 
between the more stable of lines 3 or 4 to the more stable of lines 1 
or 2) and AHz is the affinity of the dianions. They are calculated for 
eqns 1 and 2 as differences between products and the more stable 
reactants. The value of AHdH+) is 365.7 kcal/mol [31]. AAH1 and 
AAHZ are, respectively, the differences of proton affinities for first 
and second ionizations with respect to pepsin: more positive values 
are equivalent o lower acidities 
3. RESULTS AND DISCUSSION 
Enthalpies of deprotonation [31] are calculated for 
the reactions: 
AH2 * H+ + AH- (I) 
AH- e H+ + A-2 (2) 
where AH2 is the neutral active site and AH- is the 
mono-ionized one. The results for total and deprotona- 
tion enthalpies are listed in table 2. Entropies were not 
calculated but are expected to be equal for models 
which are based on the same structure [31]. The 
calculated deprotonation enthalpies are thus a 
reasonable measure of the ‘gas phase’ acidity in the im- 
mediate vicinity of the active site residues. We have 
previously shown the similarity of acidities in the 
various pepsins and found that the alternative acidities 
of the aspartates (i.e. deprotonation of Asp-32 or 
Asp-215) are equally affected by water molecules [31]. 
We conclude that the calculated deprotonation en- 
thalpies reflect intrinsic acidities which differ among 
the AP in this study. The proton affinity differences 
between pepsin and the other enzymes reflect the 
charge redistribution as a result of mutating the 
residues of pepsin, Ser-35 and Thr-218 to alanines. 
between the overall enthalpies of those two (columns 3 
and 4 in table 2). In pepsins, alternative acidities of 
Asp-32 (difference between values on lines 1 and 3 in 
column 1, table 2) and Asp-215 (difference between 
lines 2 and 4) are neariy equal due to the approximately 
symmetrical hydrogen bonding arrangement in their 
vicinity. The same is found for the model active site of 
general retroviral AP and from the model of HIV-l 
AP. In human renin, the asymmetric transformation of 
only one H-bonding residue (Thr-218) results in a 
preferential ionization of Asp-32. The active site first 
and second acidities of h. renin and of retroviral AP are 
thus found to be lower than those of pepsin due to less 
hydrogen bonding to the aspartates. This result 
generally correlates with the experimental pH profiles 
for these enzymes [7,11,14]. The source of pH variation 
is, however, more complex: the optimum for mouse 
submaxillary gland renin is -8.0 [36] with both H- 
bonding residues Ser-35 and Ser-218 present, and a 
signific~tly different propo~ion of basic to acidic 
residues exists in different AP [20]. However, the ex- 
perimental pH profiles for AP are not measured under 
equal conditions, as the substrate of each aspartic pro- 
tease is different [14]. 
From the results, we conclude that the active site of 
pepsins is the most acidic of the 3 due to the supportive 
H-bonding from Ser-35 and Thr-218. Both the active 
site model of HIV-l AP, based on RSV AP coordinates 
and the model based on endothiapepsin (‘general AP’) 
are less acidic than pepsin, despite the large differences 
The enthalpies determined in this study are a measure 
of proton interactions with the active site aspartates. 
While a proton carries a relatively large positive charge, 
inhibitor atoms can be positively charged to a smaller 
extent which will result in corresponding but smaller 
differences of interaction energies with the active sites 
in the 3 enzymes. A general choice for designing in- 
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hibitors, while exploiting this property, would be 
neutral or positively charged molecules with proton- 
donating groups. Thus, in addition to the present at- 
tempts to design specific inhibitors which are peptide 
analogs and interact with different subsites of AP, our 
results support a basis for designing smaller, non- 
peptide novel inhibitors which can interact specifically 
with the immediate vicinity of AP active sites. Based on 
our results, we expect that hydrogen bonding by an in- 
hibitor to the mono anionic state of the active site 
should be stronger in HIV-l AP and in h. renin than in 
pepsins. 
Acknowledgement: This work was supported by the Mutual Fund of 
the Hebrew University Research and Development Authority. 
REFERENCES 
[l] Kostka, V. ed. (1985) Aspartic Proteases and their Inhibitors, 
De Gruyter, Berlin. 
[2] Tang, .I. and Wong, R.N.S. (1987) _I. Cell. Biochem. 33,53-63. 
[3] Aoyagi, T., Yasigawa, Y., Kumagai, M., Hamada, M., 
Morishima, H., Takeuchi, T. and Umezawa, H. (1973) J. 
Antibiot., Tokyo 26, 539-541. 
[4] Katoh, I., Yasunaga, T., Ikawa, Y. and Yoshinaka, Y. (1987) 
Nature 329, 654-656. 
[5] Seelmeier, S., Schmidt, H., Turk, V. and Van der Helm, K. 
(1988) Proc. Natl. Acad. Sci. USA 85, 6612-6616. 
[6] Kay, J., Jupp, R.A., Norey, C.G., Richards, A.D., Reid, 
W.A., Taggart, A.T., Sanleff, I.M. and Dunn, B.M. (1988) in: 
Proteases II: Potential Role in Health and Disease (Hohl, W.H. 
and Heidland, A. eds) pp.l-11, Plenum, New York. 
[7] Darke, P.L., Leu, C.-T., Davis, L. J., Heimbach, J.C., Diehl, 
R.E., Hill, W.S., Dixon, R.A.F. and Sigal, I.S. (1988) J. Biol. 
Chem. 264, 2307-2312. 
[8] Pearl, L.H. and Taylor, W.R. (1987) Nature 329, 351-354. 
[9] Navia, M.A., Fitzgerald, P.M.D., McKeever, B.M., Leu, T.- 
C., Heimbach, J.C., Herber, W.K., Sigal, IS., Darke, P.L. 
and Springer, J.P. (1989) Nature 337, 615-620. 
[lo] Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, 
B.K., Baldwin, E., Weber, I.T., Selk, L.M., Clawson, L., 
Schneider, J. and Kent, S.B.H. (1989) Science 245, 616-621. 
[ 1 l] Richards, A.D., Roberts, R., Dunn, B.M., Graves, M.C. and 
Kay, J. (1989) FEBS Lett. 247, 113-117. 
[12] Schneider, J. and Kent, S.B.H. (1988) Cell 54, 363-368. 
[ 131 Miller, R.P., Poper, C. J., Wilson, C. W. and DeVito, E. (1972) 
Biochem. Pharmacol. 21, 2941-2944. 
[14] Maibaum, J. and Rich, D.H. (1988) J. Med. Chem. 31, 
625-629. 
]151 
1161 
1171 
I181 
WI 
m 
WI 
WI 
1231 
1241 
[251 
WI 
1271 
WI 
WI 
[301 
1311 
1321 
(331 
[341 
I351 
Bott, R., Subramanian, E. and Davies, D.R. (1982) 
Biochemistry 21, 6856-6962. 
James, M.N.G. and Sielecki, A.R. (1983) J. Mol. Biol. 163, 
299-361. 
Pearl, L. and Blundell, T.L. (1984) FEBS Lett. 174, 96-101. 
James, M.N.G. and Sielecki, A.R. (1985) Biochemistry 24, 
3701-3713. 
Suguna, K., Bott, R.R., Padlan, E.A., Subramanian, E., 
Sheriff, S., Cohen, G.H. and Davies, D.R. (1987) J. Mol. Biol. 
196, 877-900. 
Sielecki, A.R., Hayakawa, K., Fujinaga, M., Murphy, M.E.P., 
Fraser, M., Muir, A.K., Carilli, C.T., Lewicki, J.A., Baxter, 
J.D. and James, M.N.G. (1989) Science 243, 1346-1351. 
Miller, M., Jaskolski, M., Rao, J.K.M., Leis, J. and 
Wlodawer, A. (1989) Nature 337, 576-579. 
James, M.N.G., Sielecki, A.R., Salituro, F., Rich, D.H. and 
Hofman, T. (1982) Proc. Natl. Acad. Sci. USA 79,6137-6141. 
Foundling, S.I., Cooper, J., Watson, F.E., Cleasby, A., Pearl, 
L.H., Sibanda, B.L., Hemmings, A., Wood, S.P., Blundell, 
T.L., Valler, M. J., Norey, C.G., Kay, J., Boger, J., Dunn, 
B.M., Leckie, B. J., Jones, D.M., Atrash, B., Hallet, A. and 
Szelke, M. (1987) Nature 327, 349-352. 
Blundell, T.L., Cooper, J., Foundling, S.I., Jones, D.M., 
Atrash, B. and Szelke, M. (1987) Biochemistry 26, 5584-5590. 
Carlson, W.D., Hardschumacher, M., Summers, N., Karplus, 
M. and Haber, E. (1987) J. Cardiovasc. Pharmacol. 10, 
s91-s93. 
Haber, E., Hui, K.Y., Carlson, W.D. and Bernatowicz, MS. 
(1987) J. Cardiovasc. Pharmacol. 10, s54-~58. 
Akhane, K., Umeyama, H., Nakugawa, S., Moriguchi, I., 
Hirose, S., Iizuka, K. and Murakami, K. (1985) Hypertension 
7, 3-12. 
Plattner, J.J., Marcotte, P.A., Kleinert, H.D., Stein, H.H., 
Greer, J., Bolis, G., Fung, A.K.L., Bopp, B.A., Luly, J.R., 
Sham, H.L., Kempf, D.J., Rosenberg, S.H., Dellaria, J.F., 
De, B., Merits, I. and Perun, T.J. (1988) J. Med. Chem. 31, 
2277-2288. 
Weber, I.T., Miller, M., Jaskolski, M., Leis, J., Skalka, A.M 
and Wlodawer, A. (1989) Science 243, 928-931. 
Goldblum, A. (1987) J. Comp. Chem. 8, 835-849. 
Goldblum, A. (1988) Biochemistry 27, 1653-1658. 
Goldblum, A. (1988) Biochem. Biophys. Res. Commun. 159, 
450-460. 
Bernstein, F.C., Koetzle, T.F., Williams, G.J.B., Meyer, E.F., 
jr, Brice, M.D., Rodgers, J.R., Kennard, 0.. Shimanuchi, T. 
and Tasumi, M. (1977) J. Mol. Biol. 112, 535-542. 
Carlson, W., Karplus, M. and Haber, E. (1985) Hypertension 
7, 13-26. 
Dewar, M.J.S. and Thiel, W. (1977) J. Am. Chem. Sot. 99, 
4899-4907. 
[36] Ondetti, M.A. and Cushman, D.W. (1982) Annu. Rev. 
Biochem. 51, 283-308. 
244 
